Infected Blood Inquiry Additional Report: Government Response
This page details the Government's response to the Infected Blood Inquiry’s Additional Report on 9 July 2025.
The Cabinet Office, Department of Health and Social Care, and the Infected Blood Compensation Authority are implementing recommendations from the Infected Blood Inquiry report, which investigated contaminated blood products supplied to NHS patients. The response focuses on establishing functioning compensation mechanisms and securing additional funding, with implementation of Recommendation 9 being a key priority.
This page details the Government's response to the Infected Blood Inquiry’s Additional Report on 9 July 2025.
This document details the Government's response to the recommendations made by the Infected Blood Inquiry
These reports were produced by the Infected Blood Inquiry Response Expert Group to advise on design of the Infected Blood Compensation Scheme. This page also includes the Infected Blood Inquiry Response Expert Group meeting minutes, which should be read in …
Infected Blood Inquiry Response Expert Group Addendum Report - February 2025
Secretary of State for Health and Social Care, Victoria Atkins says the department will study the report to make sure lessons are learned.
In response to: Joint Communique on the Infected Blood Inquiry
Seeks views on the new special appeals mechanism that offers financial and other support for those with chronic hepatitis C infection.
Seeks views on the new special appeals mechanism that offers financial and other support for those with chronic hepatitis C infection.
Seeks views on the new special appeals mechanism that offers financial and other support for those with chronic hepatitis C infection.
Seeks views on the reforms to the support for those affected by hepatitis C or HIV from historic NHS blood treatments.
Seeks views on the reforms to the support for those affected by hepatitis C or HIV from historic NHS blood treatments.
Seeks views on the reforms to the support for those affected by hepatitis C or HIV from historic NHS blood treatments.